We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$64.9M
Cap. Flow %
3.27%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7 quarters
Top 10 Avg Time Held Equity + Options
5.1 quarters
Top 20 Avg Time Held Equity + Options
6.3 quarters
Avg Time Held Equity only
4.9 quarters
Top 10 Avg Time Held Equity only
5.1 quarters
Top 20 Avg Time Held Equity only
6.4 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO icon
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Miscellaneous 3.45%
3 Consumer Staples 0.19%
4 Consumer Discretionary 0.06%
5 Energy 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DERM icon
176
DELISTED
Dermira, Inc.
DERM
– –
-115,583
Closed -$3.94M –
GNMX icon
177
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-940
Closed -$2K –
CBM
178
DELISTED
Cambrex Corporation
CBM
– –
-9,515
Closed -$524K –
ALDR
179
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-384,169
Closed -$7.99M –
ARRY icon
180
DELISTED
Array Biopharma Inc
ARRY
– –
-25,510
Closed -$228K –
SGYP
181
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-978,100
Closed -$4.56M –
CASC
182
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-1,966
Closed -$8K –
RXDX
183
DELISTED
Ignyta, Inc.
RXDX
– –
-6,584
Closed -$57K –
PPHMP
184
DELISTED
Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
– –
-200,000
Closed -$4.34M –
CBPO
185
DELISTED
China Biologic Products Holdings, Inc.
CBPO
– –
-236
Closed -$24K –
TNGN
186
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
– –
-1,826,399
Closed -$3K –
XIV
187
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
– –
-16
Closed -$1K –
4 5 6 7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.